Premium
The absolute percent deviation of IGHV mutation rather than a 98% cut‐off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab
Author(s) -
Gocke Christopher D.,
Gladstone Douglas E.
Publication year - 2018
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15015
Subject(s) - ighv@ , fludarabine , chronic lymphocytic leukemia , chemoimmunotherapy , alemtuzumab , medicine , oncology , rituximab , immunology , immunoglobulin heavy chain , biology , cyclophosphamide , antibody , leukemia , chemotherapy